In a deal that underscores the accelerating globalization of pharmaceutical innovation, Bristol Myers Squibb (BMS) and Jiangsu Hengrui Pharmaceuticals have entered into a landmark strategic collaboration and licensing agreement valued at up to $15.2 billion. Announced on May 12, 2026, the partnership encompasses 13 early-stage programs across oncology, hematology, and immunology—representing one of the largest cross-border biopharma alliances of the year.
The transaction is anchored by a $600 million upfront payment from BMS to Hengrui, followed by two anniversary payments of $175 million each (totaling $350 million). Beyond these guaranteed payments, the deal carries potential milestone and option exercise value that could push the total to approximately $15.2 billion. Hengrui will also receive tiered royalties on net sales of products developed outside its home territory.
The 13 programs are structured in three tiers: four Hengrui-originated oncology/hematology assets (BMS gets global rights outside China/HK/Macau), four BMS-originated immunology assets (Hengrui gets China rights), and five jointly discovered programs. All are preclinical stage.
For BMS, the deal diversifies late-stage pipeline risk by accessing China's maturing drug discovery ecosystem. For Hengrui, it represents a major step in global expansion—since 2023, Hengrui has secured 12 overseas licensing transactions exceeding $27 billion in cumulative value.
As 13 preclinical programs advance toward IND filings, demand for complex synthesis, advanced intermediates, and custom APIs will increase. CDMO partners with multi-step synthesis and HPAPI capabilities stand to benefit.
